ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Moat Score: 0/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:EXPRS2 ExpreS2ion Biotech Holding AB OSTO:EXPRS2
43 GF Score
Price kr1.46
GF Value kr3.44
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ExpreS2ion Biotech Holding AB Moat Score?

ExpreS2ion Biotech Holding AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

ExpreS2ion Biotech Holding AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes ExpreS2ion Biotech Holding AB might have No Moat - No discernible moat.

ExpreS2ion Biotech Holding AB  (OSTO:EXPRS2) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

ExpreS2ion Biotech Holding AB Moat Score Related Terms

OSTO:EXPRS2
43GF Score
ExpreS2ion Biotech Holding AB OSTO:EXPRS2
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?

Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued. The current stock price of kr1.46 is trading 57.6% below its estimated GF Value™ of kr3.44. GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.

Key valuation signals for OSTO:EXPRS2:

  • Moat Score: 0
  • GF Value™: kr3.44 vs. price of kr1.46 (57.6% below fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ExpreS2ion Biotech Holding AB Business Description

Other Exchanges 5JD0:Germany
Address c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, 252 25
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score

Get the complete analysis for OSTO:EXPRS2

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.46
Price
kr3.44
GF Value